Cancer Expenditures and Mortality Trends in Brazil: An Ecological Population‐Level Time‐Series Analysis, 2008–2023

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT Background Brazil has substantially expanded public oncology investment over the past decade, particularly within the Brazilian Unified Health System (SUS). However, whether increased spending has translated into measurable population‐level improvements in cancer outcomes remains uncertain. Methods We conducted a retrospective ecological time‐series analysis using national data from 2008 to 2023. Public expenditures for female breast and prostate cancer were extracted from DATASUS and inflation‐adjusted, while mortality data were obtained from INCA and age‐standardized. Key policy milestones—RDC 55/2010, creation of Conitec in 2011, Ordinance No. 874/2013, and Constitutional Amendment 95/2016—were mapped against expenditure and mortality trends. Findings therefore represent system‐level associations rather than causal estimates of patient‐level therapeutic effectiveness. Results Oncology expenditures increased substantially, with more pronounced growth after 2011, whereas national age‐standardized mortality rates for female breast and prostate cancer changed comparatively little. This pattern represents a descriptive temporal divergence between expenditure growth and mortality trends, not evidence of therapeutic inefficacy or a quantified causal effect. Regional differences in diagnostic capacity, healthcare infrastructure, continuity of care, and treatment timeliness may influence how financial inputs translate into population‐level outcomes. Conclusions Brazil's experience supports a value‐oriented oncology strategy linking investment not only to technology incorporation, but also to early diagnosis, implementation capacity, regional equity, and effective care pathways. These ecological findings do not support individual‐level causal inference, particularly for prostate cancer, for which mortality is a delayed and relatively insensitive medium‐term endpoint. Future studies should incorporate stage at diagnosis, treatment pathways, time‐to‐treatment indicators, and regional survival data.